The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - YmAbs Therapeutics Inc
Intraventricular radioimmunotherapy targeting B7H3 for CNS malignancies.
 
Kim Kramer
Consulting or Advisory Role - Ymabs Therapeutics Inc
Travel, Accommodations, Expenses - Ymabs Therapeutics Inc
 
Neeta Pandit-Taskar
No Relationships to Disclose
 
Maria Donzelli
No Relationships to Disclose
 
Suzanne L. Wolden
Travel, Accommodations, Expenses - IBA
 
Pat Zanzonico
No Relationships to Disclose
 
John Humm
No Relationships to Disclose
 
Sofia Haque
Honoraria - Advance Medical
Consulting or Advisory Role - Advance Medical
 
Mark M. Souweidane
Consulting or Advisory Role - Aesculap
Travel, Accommodations, Expenses - Aesculap
 
Jason Lewis
No Relationships to Disclose
 
Serge K. Lyashchenko
Consulting or Advisory Role - Y-mAbs Therapeutics
 
Steven M. Larson
Stock and Other Ownership Interests - ImaginAb
Consulting or Advisory Role - Prescient Therapeutics
Research Funding - Regeneron; Wilex
Patents, Royalties, Other Intellectual Property - Antigen-Specific Composition and In Vivo Methods for Detecting and Localizing an Antigenic Site and for Radiotherapy. Larson SM, Finn R, Carrasquillo JA, Reynolds JC, Neumann RD, Graham MC, Pentlow KS. U.S. Patent No. 5,185,142. Date: Feb. 9, 1993.; Multi-Specific Antibodies with Affinity for Human A33 Antigen and DOTA Metal Complex and Uses Thereof . Cheal S, Hong Xu, Larson SM, NK Cheung. US Patent No. 62,113,988. Date 2/09/2015.; Non-invasive imaging and Quantification of Specific Antigen and Uses Thereof. Smith-Jones, P and Larson SM. Provisional Patent Application. Registration Number 28,325. Date 1/06/03.; Single chain Fv polynucleotide or peptide construct of anti-ganglioside GD2 antibodies, cells expressing same and related methods NK Cheung, SM Larson, HF Guo, K Rivlin, M. Sadelain US Patent No. 6,451,995.; Small-Molecule HSP90 Inhibitors, Chiosis, Gabriela; Huazhong He, Llauger-Bufi, Laura; Kim Joungnam; Larson, Steve; Smith-Jones, Peter. US Patent No. 7,834,181. Date 11/16/10.; Synthesis and Utilization of 17-methyl and 17-cyclo-propylmethyl-3, 14-Di-hydroxy-4, 5-Epoxy 6 b-Fluoromorphines (Foxy and cyclofoxy) as (18F)-labeled opiate ligands for positron emission transaxial tomography. (PET) Rice KC, Pert CB, Burke TR, Jr., Larso; Systems and Methods for Determining Optimum Patient-Specific Antibody Dose for Tumor Targeting. Zanzonico P, Cheal SM, Larson SM, Osborne J, Fung Edward K. US Patent No. 62,165699. Date 5/22/2015
Travel, Accommodations, Expenses - Voreyda Theranostics
 
Nai-Kong V. Cheung
Stock and Other Ownership Interests - Ymabs Therapeutics Inc
Consulting or Advisory Role - AstraZeneca/MedImmune
Research Funding - Ymabs Therapeutics Inc (Inst)
Patents, Royalties, Other Intellectual Property - affinity matured hu8H9 (Inst); anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof (Inst); anti-GD2 antibodies (Inst); bispecific HER2 and CD3 binding molecules (Inst); GD2 peptide mimics (Inst); generation and use of HLA-A2–restricted peptide-specific mAbs and CARs (Inst); high-affinity anti-GD2 antibodies (Inst); methods for detecting MRD (Inst); methods for preparing and using scFv (Inst); multimerization technologies (Inst); ROR2 antibodies (Inst); scfv constructs of anti-GD2 antibodies (Inst); therapy-enhancing glucan (Inst); use of mAb 8H9 (Inst)